No. 051 · Combos · Peptide Blend
CJC-1295 DAC + Ipamorelin
- Not approved as a combo
- WADA ✗ S2
Combos are blends of separate compounds, so there is no single sequence. This ring motif is decorative — open a component for its fingerprint.
Evidence
- D In vitro
- C Animal
- B Human pilot
- A RCT
- S Approved
Not ranked: combinations have no published studies of their own. See the components below.
A PubMed search found no published studies of this combination; only reviews mention it. CJC-1295 (with DAC) and ipamorelin each have small human pharmacology studies.
Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.
At a glance
- Routes studied
- Subcutaneous, Intramuscular Routes used in published research
- FDA
- Not approved as a combination
- WADA
- Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
Overview
One of the most popular GH secretagogue stacks, combining a long-acting GHRH analog with a selective GHRP for sustained, synergistic growth hormone elevation.
Research status No published studies of the combination; CJC-1295 (DAC) has a randomized dose-escalation trial in healthy adults and ipamorelin has small human pharmacokinetic studies
Mechanism
This blend exploits synergy between GHRH and GHRP pathways. CJC-1295 DAC activates the GHRH receptor via cAMP/PKA signaling for sustained GH release (half-life 6-8 days due to albumin binding), while ipamorelin activates the ghrelin receptor (GHS-R1a) via IP3/PKC. Together they produce amplified GH pulses exceeding either component alone.
Effects reported in research
These outcomes are attributed to the individual components. The combination itself has not been studied.
- Sustained and amplified GH release
- Improved body composition and fat loss
- Enhanced deep sleep and recovery
- Increased IGF-1 levels
Safety & unknowns
Both components have individual clinical trial data. Common side effects: water retention, tingling, headache, flushing. CJC-1295 DAC provides sustained GH elevation which may increase IGF-1 beyond physiological levels. Ipamorelin adds minimal cortisol/prolactin risk. Not FDA-approved as a combination.
Unknowns. The combination itself has not been studied; interactions between its components are unknown.
Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.
Studies [2]
- Clinical trial 2006
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Two randomized placebo-controlled ascending-dose trials of the CJC-1295 (DAC) component in healthy adults: a single injection raised GH 2- to 10-fold for 6 days or more and IGF-I for 9–11 days (half-life 5.8–8.1 days).
- Preclinical 1998
Ipamorelin, the first selective growth hormone secretagogue
Rat and swine study on the ipamorelin component: it released GH as effectively as GHRP-6 but, unlike GHRP-6 and GHRP-2, did not raise ACTH or cortisol.
Components
Status sources
Sources behind the tier, regulatory status, sequence and dates on this page.
- Teichman et al. 2006 — CJC-1295 in healthy adults pubmed.ncbi.nlm.nih.gov
- Gobburu et al. 1999 — ipamorelin PK/PD in human volunteers pubmed.ncbi.nlm.nih.gov
- WADA 2026 Prohibited List — S2.2.4 names CJC-1295 and ipamorelin wada-ama.org
Cite this entry
peptidemeta. (2026). CJC-1295 DAC + Ipamorelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/cjc-1295-dac-ipamorelin/
@misc{peptidemeta-cjc-1295-dac-ipamorelin,
title = {CJC-1295 DAC + Ipamorelin},
author = {{peptidemeta}},
year = {2026},
howpublished = {\url{https://peptidemeta.com/p/cjc-1295-dac-ipamorelin/}},
note = {Accessed 2026-11-08}
} Accessed date reflects when you opened this page. Cite primary studies for scientific claims.